Metformin did not prevent frailty progression in a 16-week RCT of pre-frail elderly
This was a randomized controlled trial testing whether metformin over 16 weeks could prevent frailty progression in non-diabetic pre-frail older adults. The study measured frailty status, quality of life, handgrip strength, gait speed, and serum myostatin levels. However, the abstract does not report the actual results, effect sizes, or whether the hypothesis was supported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 14, 2016 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 4 months
- Population
- Pre-frail non-diabetic elderly
- Primary outcome
- Frailty status
- Effect size
- —
- Significance
- Not reported
- Journal
- Indonesia University
- Published
- Sep 14, 2016
Sources
Primary source
- Indonesia University ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.